Health regions in Canada are primarily associated with the rationalization of conventional, historically expensive provincial health care systems. At the same time, it is unclear what contribution health regions make to advancing health system reform, particularly health-promoting activities. This work sets out to understand the relationships between regionalization and health-promoting activity by studying two health regions in Canadian provinces that have different approaches to regionalization (British Columbia and Ontario). I use a constructivist grounded theory methodology (Charmaz, 2006) to analyse data from nineteen key informant interviews with senior management working in the two regional health authorities and in provincial health organizations. The iterative analysis of the empirical data and the review of corporate documents from both regional organizations result in the identification of three core themes grounded in the data. The dominant theme emerging from the analysis is identified as place-making referring to a region’s ability to facilitate health-promoting activity by making the region a place with special meaning and resonance for the populations served. The other two themes are creating space within organizations for health-promoting activity and developing networks. The former refers to a region’s willingness and ability to operationally support health-promoting activity and the latter refers to efforts undertaken to establish relationships with other organizations in the health-promotion and healthcare networks. I conclude that these three themes characterize critical components of a therapeutic region. A therapeutic region suggests a conceptualization of regional health authorities (RHAs) in which priority is given to health-promoting activities, alongside an entrenched curative healthcare agenda (the medical model). A therapeutic region is conceived of as a region that implements policies and develops structures aimed at achieving improvements in the overall health status of the population it serves. In this research I develop a four-cell matrix to frame the theory of therapeutic regions. One axis represents a continuum of place-making, while the second axis reflects a continuum depicting how regions develop the two other themes -- one extreme represents a piecemeal or patchwork approach, and the other an integrated strategic approach. The implications of this research relate to practice and policy. The practice of improving the health of the population served requires regions to open pathways, and remove longstanding barriers by making place-making core to all community engagement and develop health-promoting activity within their organizations and their networks. Policy-makers need to bring clarity to the regions’ role in health-promoting activity. This research indicates that health-promoting activity, innovation and progress occur when a region has the ability to manage both conventional, curative health care and health-promoting activities. Whether that is through direct governance or new ways to bring together decision-making, service co-ordination and evaluation is a subject for future work. / Graduate

分娩痛是一種生理性的疼痛，分娩過程中劇烈疼痛痛苦難以忍受，同時使產婦焦慮、緊張和恐懼，致使產婦血中兒茶酚胺、腎上腺皮質激素增高，導致血壓升高，心臟負荷加重﹔產婦由於疼痛呼喊、過度換氣、耗氧量增加，可導致呼吸性堿中毒，從而影響胎盤血供，導致母兒出現低氧血症。隨著產程進展、疼痛加劇，產婦血壓升高、呼吸頻率增快，過度耗氧，引起胎兒宮內窘迫，種種危險和痛苦導致剖宮產率逐年上升，加之藥物麻醉對產婦和胎兒都可以產生一定的不良反應。因此，合理地運用適當的疼痛緩解措施，可以使疼痛應激反應減輕甚至消失，提 高圍產期品質，分娩鎮痛日益受到重視。 研究目的 研究希望通過對現有關於通過穴位進行分娩鎮痛的臨床研究類文獻搜集、整理、分析，從而對通過穴位分娩鎮痛的常用方法、常用穴位、有效率等等方面做一個較為全面的展示，並對當前通過穴位分娩鎮痛的臨床研究的現狀和可能存在的問題進行探討。 方法 以中國期刊全文資料庫進行標準檢索，檢索選項為“主題”，檢索詞為“針刺”or“穴位”並包含“分娩鎮痛”or“分娩痛”，時間年限設定為2004年－2014 年。按納入排除標準進一步篩選文獻。 小結 就通過穴位分婉鎮痛的常用方法、常用穴位、有效率、產程變化、產後出血量等等方面進行文獻研究總結後，發現近年來通過穴位分娩鎮痛的臨床實驗文獻逐漸增多，初步證明穴位分娩鎮痛安全有效，但目前可搜到的臨床文獻存在臨床研究方式較為單一、選穴單一、結論標準不統一、隨機對照試驗設計不嚴謹等等問題，提示我們進行進一步研究。 關鍵字：分娩鎮痛﹔針刺鎮痛﹔ 穴位鎮痛﹔ 分娩痛﹔

A research report submitted to the Faculty of Health Sciences, University of the Witwatersrand, in partial fulfilment of the requirements for the degree of Master of Science in Medicine (Pharmaceutical Affairs) Johannesburg, 29 August 2014 / In South Africa’s current healthcare structure, about 8.3% of GDP is spent on healthcare. This is well above the WHO recommended 5% of GDP spend. Despite the heavy spending, health outcomes remain poor when compared to similar middle-income countries. Solutions need to be found to cut back on healthcare costs. Approximately half (4.1%) of the healthcare spend is consumed by the private sector which benefits a very small segment (16%) of the population. This segment is largely on medical schemes. Using generic medicines can aid in cutting back on drug costs but are generics being adequately assimilated by the consumers of healthcare in the private sector? The objective of the study was to evaluate the perceptions attitudes and knowledge of the consumers of healthcare in the Northern suburbs of Johannesburg towards generic medicines. A survey was conducted on a sample of 402 respondents across 9 randomly selected pharmacies in the Johannesburg north region between November 2012 and February 2013. A researcher administered questionnaire was the sole data collection tool. Questions asked covered the research objectives and also included demographic data and other explanatory variables. Data analysis was carried out in SAS. The 5% significance level was used throughout, unless specified otherwise. The chi-squared (Χ2 ) test was used to assess the relationships between categorical variables. Fisher’s exact test was used for 2 x 2 tables or where the requirements for the Χ2 test could not be met. The strength of the associations was measured by Cramer’s V and the phi coefficient respectively. Key results on respondent demographics included high representation of the higher income earning groups (78% >R10 000); furthermore 44% had completed tertiary education, 60% were comprehensively insured, 61% regularly visited a pharmacy, 38% were on prescription medication and 24% on chronic medicine. On knowledge, 5% of respondents were able to most accurately define generic medicines. On attitudes, 78% had used generics however the level of agreement was lower for the highest education category (p<0.0001; Cramer’s V=0.18). Trends favoured brands over generics with increasing severity of illness as generics were chosen by 10% in major illness and 5% in chronic illness. 80% perceived generics as safe while 95% perceived brands as safe. 75% of respondents felt that generic medicines were as effective as branded medicines. 15% indicated that branded medicines have fewer side effects. 64% showed positive perceptions of quality of generics compared to 93% for brands. Bowker’s test of symmetry was significant (p<0.0001) showing a shift towards slightly more negative perceptions towards generic medicines amongst those who thought highly of brand quality. Knowledge of generics was overall low. Perceptions regarding safety, quality, efficacy, and side effects of generic medicines were generally positive but responses proved more positive for brands. Attitudes towards generic medicines were mostly positive however willingness to use generics lessened with increasing severity of illness. Household income, health insurance (medical aid) status, level of education, experience with medicines and racial demographics played a key role in explaining consumer beliefs and behaviours. Pharmacists and Doctors had a positive influence on generic use patterns amongst other factors.

A dissertation submitted to the Faculty of Health Sciences, University of Witwatersrand, School of Physiology in fulfilment of the requirements for the degree of Master of Science in Medicine. Johannesburg, 2014 / Sedentary lifestyles and poor dietary choices are the major cause of the global increase in the prevalence of obesity and metabolic dysfunction in children. The high cost and limited access to conventional drugs by poor communities make them depend on ethnomedicines. Terminalia sericea (T. sericea) contains phytochemicals that give its extracts hypolipidaemic and hypoglycaemic properties hence its use in ethnomedicine to treat diabetes mellitus. Using weanling Wistar rat pups fed a high fructose diet to model growing children exposed to high-sugar diets, this study sought to evaluate the effects of aqueous T. sericea leaf extracts on their growth performance, glucose homeostasis, visceral morphometry and their general health profile. Forty 21-day old male Wistar pups were randomly allocated to five treatment regimens. Each group had ad libitum access to a commercially supplied rat chow. Group 1 pups were given plain drinking water and plain gelatine cubes, group 2: 12% fructose solution and plain gelatine cubes, group 3: 12% fructose solution and gelatine cubes containing fenofibrate at a dosage of 100 mg.kg-1 per day, group 4: 12% fructose solution and gelatine cubes with a low dose (100 mg.kg-1 per day) of the T. sericea extract and group 5: 12% fructose solution and gelatine cubes with a high dose (400 mg.kg-1 per day) of the T. sericea extract. The pups were maintained on the regimens for 12 weeks after which they under went an oral glucose tolerance test. Fasting blood metabolite content was then determined after which the rats were killed and tissues collected for visceral morphometrical, linear growth and surrogate markers’ of health determinations. T. sericea extracts had no negative effect on growth performance (body mass and indexes of long bone growth) but rats given fenofibrate had lighter empty carcasses and shorter tibiae. vi The administration of T. sericea extracts neither improved glucose homeostasis nor caused derangement of glucose handling by rats given a high fructose diet following an oral glucose challenge. However, the administration of fenofibrate to rats given a high fructose diet resulted in decreased glucose handling following an oral glucose challenge. With the exception of the administration of fenofibrate which resulted in a significantly high (P < 0.05) fasting blood glucose concentration, treatment regimens had no effect on fasting blood glucose, triglyceride and cholesterol concentrations. Rats given fructose with either plain gelatine cubes or low T. sericea dose had significantly higher (P < 0.05) liver lipid content compared with the control treatment. Administration of T. sericea extracts to rats given a high fructose diet had no effect on the GIT, other abdominal viscera and markers of general health. The administration of fenofibrate to rats given a high fructose diet caused increased relative mass of GIT organs (stomach, small intestine and caecum), increased absolute mass of other viscera (liver and kidney); increased serum phosphorus and alkaline phosphatase concentration. Results from the study revealed that administration of a high dose of aqueous T. sericea leaf extracts has potent phytochemicals properties that has helped to prevent high fructose diet-induced deposition of fat in the in the liver (non-alcoholic fatty liver disease), without compromising growth, visceral morphometry and general health of growing Wistar rats.

A thesis submitted to the Faculty of Science, University of the Witwatersrand, Johannesburg, in fulfillment of the requirements for the degree of Doctor of Philosophy of Science. Johannesburg, 2013 / Chemotherapy, while representing a vital component of cancer treatment modalities, has so far not fulfilled basic expectations with unsatisfactory cure rates and frequent relapse due to limited effectiveness of the therapeutic drugs, severe side effects and resistance problems. The platinumcontaining drugs used in present clinical practice are no exception to this generalized finding. While highly effective against a small number of malignancies, they generally share in the deficiencies of other anticancer agents. To address this issue, intense research is being undertaken to develop novel platinum-compounds offering enhanced therapeutic effectiveness. To accomplish this, several new avenues of development are being pursued world-wide, and one of these involving the binding of monomeric anticancer drug systems to water-soluble, biocompatible and biodegradable polymeric carriers, was utilized in the current research. As part of the ongoing research, this dissertation demonstrates the preparation of several water-soluble polymeric carriers bearing pre-synthesized monomers aimed to anchor the platinum drug. The monomers of interest were aspartic acid, p-aminobenzoic acid and p-aminosalicylic acid derivatives; while the water-soluble carriers were polyaspartamides, prepared by an aminolytic ring-opening process of polysuccinimide. The platination agents were conjugated to the polymer backbone both via amine and via leaving-group ligands, such as dihydroxylato, dicarboxylato and carboxylatohydroxylato. In order to demonstrate the multidrug-binding capacity of the carriers, platinum complexes were co-conjugated to polymeric conjugates containing ferrocene. The in vitro studies against a human breast cancer (MCF-7) cell line showed IC50 values ranging from 48.92 μg.mL-1 to 281.37 μg.mL-1 for the platinum conjugates, 13.18 μg.mL-1 to 149.67 μg.mL-1 for ferrocene conjugates and 6.22 μg.mL-1 to 83.86 μg.mL-1 for platinum/ferrocene co-conjugates; and these values were on average 4 fold more active than the parent drug. The results of these preliminary tests provide proof of the principle that polymer-drug conjugates can play a role in future cancer therapy.

A research report submitted to the Faculty of Health Sciences, University of the Witwatersrand, in partial fulfillment of the requirements for the degree of Masters of Science in Medicine in Emergency Medicine. Johannesburg, 2013 / To determine the types of uropathogens encountered in patients presenting to a busy private emergency department in Johannesburg and compare sensitivity patterns of the bacteria identified with current antimicrobial prescribing patterns.

University of Macau / Institute of Chinese Medical Sciences

Despite numerous studies have demonstrated an association of type 2 diabetes mellitus (T2DM) and osteoporosis, the underlying mechanism connecting these two conditions remains elusive. Clinically, combined calcium and vitamin D supplement is the commonest osteoporosis therapy; however, recent studies have suggested an increase in cardiovascular risks associated with calcium plus vitamin D supplementation. Therefore, an alternative strategy in treating osteoporosis patients with T2DM is urgently needed. In this study, we hypothesized that combined administration of menaquinone-4 (vitamin K₂, biologically active form of vitamin K) and 1α,25-dihydroxyvitamin D₃ (vitamin D₃, biologically active form of vitamin D) as a novel therapy in treating osteoporosis of T2DM patients. Anabolic effect of vitamin K₂ and vitamin D₃, alone or in combination, was assessed on primary osteoblasts harvested from the iliac crests of C57BL/KsJ lean (db⁺/m⁺) and obese/diabetic (db⁺/db⁺, leptin receptor-deficient) mice. Furthermore, the underlying cellular mechanism was also investigated. Serum undercarboxylated osteocalcin (an indication of vitamin K₂ level) level was higher whereas vitamin D₃ level was lower in db⁺/db⁺ mice, and sections of the iliac crests of db⁺/db⁺ mice illustrated extensive porous structures filled with enlarged adipocytes compared with db⁺/m⁺ mice. Lower levels of bone anabolic markers and bone formation transcription factors (osteocalcin, Runx2, Dlx5, ATF4, type I collagen, OSX, alkaline phosphatase (ALP) activity, p-Smad1/5/8 and p-ERK1/2) were observed in the osteoblasts of db⁺/db⁺ mice. Acute vitamin D₃ (10 nM) application elicited a more sustained and greater magnitude of increase of [Ca²⁺]ᵢ in osteoblasts of db⁺/m⁺ mice when compared with db⁺/db⁺ mice. A significantly higher level of calcium deposits in osteoblasts was observed in db⁺/m⁺ mice when compared to db⁺/db⁺ mice. Co-administration of vitamin K₂ (10 nM) and vitamin D₃ (10 nM) caused an enhancement of calcium deposits in osteoblasts in both strains of mice. Vitamins K₂ and D₃ co-administration time-dependently (7, 14 and 21 days) increased the levels of bone anabolic markers and transcription factors for bone formation, with a greater magnitude of increase observed in osteoblasts of db⁺/db⁺ mice. Suppressed expression of calcium-sensing receptor (CaSR), F-actin, V-ATPase, vitamin D receptor (VDR) and pregnane X receptor (PXR) observed in osteoblasts of db⁺/db⁺ mice were partially reversed by combined vitamins treatment. Moreover, combined vitamins K₂ plus D₃ treatment significantly enhanced migration and the appearance of surface microvilli and ruffles of osteoblasts of db⁺/db⁺ mice. Effects of combined vitamins K₂ plus D₃ treatment observed in osteoblasts of db⁺/db⁺ and db⁺/m⁺ mice were eradicated by warfarin (20 µM, a vitamin K epoxide reductase inhibitor). Thus, our results illustrate that vitamins K₂ plus D₃ supplementation is a novel therapeutic strategy in treating osteoporosis of T2DM patients. / 儘管大量研究已證明第二類型糖尿病和骨質疏鬆症的關聯，連接這兩個病症的基本機制仍然是難以捉摸的。在臨床上，鈣和維生素D的綜合補充劑是最常見的骨質疏鬆症治療，然而最近的研究卻表明服用鈣和維生素D的綜合補充劑會增加患者的心血管風險，因此急切需要尋找可以給予同時患有骨質疏鬆症和第二類型糖尿病患者的替代治療。在本研究中，我們假設甲萘醌-4（維生素K₂，維生素K生物活性形式）和1α，25 - 二羥基維生素D₃（維生素D₃，維生素D的生物活性形式）可以嘗試在同時患有骨質疏鬆症和第二類型糖尿病患者身上作為一種革新的療法。本研究從C57BL/KsJ瘦削/非糖尿病 (db⁺/m⁺) 的小鼠和肥胖/帶有第二類型糖尿病基因 (db⁺/db⁺) 兼有瘦素受體缺陷的小鼠的髂嵴原始成骨細胞上對維生素K₂和維生素D₃單獨或組合使用的合成代謝作用進行了評估。此外，我們也對該成骨細胞的底層機制進行了一系列的研究。 / 在肥胖/帶有第二類型糖尿病基因的小鼠血清內低羧骨鈣素水平（維生素K₂水平的指標）較高而維生素D水平較低，另外，它們的髂嵴的部分與瘦削/非糖尿病的小鼠相比，呈現出比較廣泛的多孔結構並填滿了擴大的脂肪細胞。從肥胖/帶有第二類型糖尿病基因的小鼠的成骨細胞中，可以觀察到它們的骨合成代謝的標誌物和骨骼形成的轉錄因子 (骨鈣蛋白，Runx2，Dlx5，ATF4，第一類型骨膠原，OSX，鹼性磷酸酶 (ALP) 活性，p-Smad1/5/8和p-ERK1/2) 的水平比較低。急性維生素D₃ (10 nM) 的應用在瘦削/非糖尿病小鼠的成骨細胞比起在肥胖/帶有第二類型糖尿病基因的小鼠的成骨細胞引起更持續和更大幅度的細胞內鈣變化增加。在瘦削/非糖尿病小鼠的成骨細胞中比起在肥胖/帶有第二類型糖尿病基因的小鼠的成骨細胞有顯著較高的鈣沉積形成。維生素K₂ (10 nM) 和維生素D₃ (10 nM) 的綜合藥在兩種小鼠的成骨細胞中可以有效地增強鈣沉積的形成。維生素K₂和維生素D₃的綜合藥對增加骨合成代謝的標誌物和骨形成轉錄因子的水平有時間依賴性 (7，14和21日)，療程越長至21日，在肥胖/帶有第二類型糖尿病基因小鼠的成骨細胞中有更大的幅度的增加。合併維生素治療能部分有效地逆轉在肥胖/帶有第二類型糖尿病基因小鼠的成骨細胞中被抑制表達的鈣敏感受體 (CASR)，F-肌動蛋白，V-ATP酶，維生素D受體 (VDR) 和孕烷X受體 (PXR)。此外，結合維生素K₂加維生素D₃治療顯著增強了肥胖/帶有第二類型糖尿病基因小鼠的成骨細胞的細胞遷移和增加了成骨細胞表面外觀的微絨毛和褶皺。在瘦削/非糖尿病小鼠的成骨細胞及肥胖/帶有第二類型糖尿病基因的小鼠的成骨細胞上結合維生素K₂加維生素D₃的治療效果被華法林 (20 μM，維生素K環氧化物還原酶抑製劑) 根除。因此，我們的結果証明了維生素K₂加維生素D₃補充劑的結合使用可有效地作為治療第二類型糖尿病患者並患有骨質疏鬆症的一種新的治療策略。 / Poon, Chui Wa Christina. / Thesis (Ph.D.)--Chinese University of Hong Kong, 2014.n5203 / Includes bibliographical references (leaves 135-151). / Abstracts also in Chinese. / Title from PDF title page (viewed on 26, October, 2016). / Detailed summary in vernacular field only. / Detailed summary in vernacular field only.

by Lee Wai Chi, Edwin. / Thesis (M.Phil.)--Chinese University of Hong Kong, 1993. / Includes bibliographical references (leaves 115-125). / Acknowledgments --- p.I / List of figures --- p.II / List of tables --- p.III / List of graphs --- p.III / Abstract --- p.VIII / Chapter I.CHAPTER ONE --- Introduction --- p.1 / Chapter 1.1 --- Electromagnetic / Magnetic field in biological interventions --- p.1 / Chapter 1.2 --- Objective of the study --- p.4 / Chapter 1.3 --- Hypothesis of the study --- p.5 / Chapter II.CHAPTER TWO --- Literature Review --- p.6 / Chapter 2.1 --- Inflammation / Chapter 2.1.1 --- Models of studying tendon injuries --- p.6 / Chapter 2.1.2 --- Methods of measuring inflammation --- p.7 / Chapter 2.1.3 --- Treatments of soft tissue inflammation --- p.9 / Chapter 2.2 --- Aspects of electromagnetic and magnetic fields / Chapter 2.2.1 --- Applications of electromagnetic / magnetic fields in soft tissue inflammation --- p.12 / Chapter 2.2.2 --- Physiological effects of electromagnetic/magnetic fields / Chapter 2.2.2.1 --- Experiments on inflammation --- p.16 / Chapter 2.2.2.2 --- Experiments on soft tissue / tendon injuries --- p.16 / Chapter 2.2.2.3 --- Experiments on blood circulation --- p.18 / Chapter 2.2.3 --- Experiments with different parameter settings of PEMF / PMF in soft tissue inflammation --- p.19 / Chapter 2.2.4 --- Proposed mechanisms of electromagnetic/magnetic fields --- p.22 / Chapter III.CHAPTER THREE --- Methods and Materials --- p.23 / Chapter 3.1 --- Animal models --- p.23 / Chapter 3.2 --- Apparatus --- p.24 / Chapter 3.3 --- Treatment Regimen --- p.27 / Chapter 3.4 --- Assessments --- p.29 / Chapter IV.CHAPTER FOUR --- Histological Assessment --- p.30 / Chapter 4.1 --- Introduction --- p.30 / Chapter 4.2 --- Methods --- p.31 / Chapter 4.3 --- Results --- p.31 / Chapter 4.4 --- Discussions --- p.45 / Chapter V.CHAPTER FIVE --- Morphometrical analysis on tissue sections with immunochemical staining --- p.51 / Chapter 5.1 --- Introduction / Chapter 5.1.1 --- Different approaches in identification of macrophages --- p.51 / Chapter 5.1.2 --- Avidin-biotin enzyme complex assay --- p.52 / Chapter 5.2 --- Methods --- p.54 / Chapter 5.2.1 --- ABC method --- p.54 / Chapter 5.2.2 --- Morphometric analysis of tissue sections --- p.55 / Chapter 5.2.3 --- Statistical method --- p.56 / Chapter 5.3 --- Results / Chapter 5.3.1 --- Immunochemical results --- p.56 / Chapter 5.3.2 --- Morphometric results --- p.60 / Chapter 5.4 --- Discussions --- p.64 / Chapter VI.CHAPTER SIX --- Biochemical Assessments --- p.67 / Chapter 6.1 --- Water content / Chapter 6.1.1 --- Introduction --- p.67 / Chapter 6.1.2 --- Methods --- p.68 / Chapter 6.1.2.1 --- Water content measurement --- p.68 / Chapter 6.1.2.2 --- Statistical method --- p.69 / Chapter 6.1.3 --- Results --- p.72 / Chapter 6.1.4 --- Discussions --- p.77 / Chapter 6.2 --- Total collagen content / Chapter 6.2.1 --- Introduction --- p.81 / Chapter 6.2.1.1 --- Hydroxyproline as an indicator for collagen content assay --- p.81 / Chapter 6.2.2 --- Methods / Chapter 6.2.2.1 --- Hydrolysis method --- p.82 / Chapter 6.2.2.2 --- Standard-curve preparation --- p.83 / Chapter 6.2.2.3 --- Statstical method --- p.84 / Chapter 6.2.3 --- Results --- p.84 / Chapter 6.2.4 --- Discussions --- p.89 / Chapter VII.CHAPTER SEVEN --- Discussion --- p.92 / Chapter VIII.CHAPTER EIGHT --- Summary and Conclusions --- p.103 / Appendix A : Histological reagents preparations --- p.106 / Appendix B : Staining procedures for standard H & E --- p.107 / Appendix C : Immunochemical staining reagents preparations --- p.108 / Appendix D : Staining procedure for StreptABComplex / HRP --- p.110 / AppendixE : Biochemical reagents and preparations --- p.111 / Appendix F : Hydrolysis method for the tendon --- p.112 / Appendix G : Standard-curve of hydroxyproline --- p.113 / Appendix H : Determination of optimal hours for collagen hydrolysis --- p.114 / REFERENCES --- p.115

by Chun-kwok Wong. / Thesis (M.Phil.)--Chinese University of Hong Kong, 1990. / Bibliography: leaves 181-196. / ABSTRACT --- p.i / ACKNOWLEDGEMENTS --- p.iii / ABBREVIATIONS --- p.iv / CHAPTER / Chapter 1. --- INTRODUCTION : An overview of Tumor Necrosis Factor ( TNF) / Chapter 1. --- The discovery of tumor necrosis factor (TNF) --- p.1 / Chapter 2. --- Production of tumor necrosis factor --- p.3 / Chapter 3. --- Physiochemical properties of TNF --- p.5 / Chapter 4. --- Biological activities of TNF on various cells in the mammal --- p.8 / Chapter 5. --- Mechanisms of anti-tumor action of TNF --- p.12 / Chapter 6. --- Clinical studies of Hr-TNF --- p.19 / Chapter 2. --- AIM OF INVESTIGATION --- p.23 / Chapter 3. --- MATERIALS AND METHODS / Chapter A. --- MATERIALS --- p.26 / Chapter B. --- METHODS / Chapter 1. --- Preparation of Reagents --- p.30 / Chapter 2. --- Cell Culture --- p.31 / Chapter 3. --- Lymphocytes proliferation --- p.32 / Chapter 4. --- In vitro production of tumor necrosis factor (TNF) by peritoneal macrophages of ICR mice --- p.33 / Chapter 5. --- Production of TNF in animals --- p.34 / Chapter 6. --- Determination of TNF titre --- p.35 / Chapter 7. --- Determination of TNF containing serum titre on EAT in vitro --- p.35 / Chapter 8. --- Mortality determination of mice --- p.36 / Chapter 9. --- "3H-Thymidine, 3H-uridine, 14C-leucine incorporation" --- p.36 / Chapter 10. --- Glucose uptake determination --- p.37 / Chapter 11. --- Whole body hyperthermic treatment of EAT bearing mice --- p.37 / Chapter 12. --- Lipolysis assay --- p.38 / Chapter 13. --- Statistical analysis --- p.39 / Chapter 4. --- IN VIVO PRODUCTION OF TUMOR NECROSIS FACTOR USING ZYMOSAN AND LIPOPOLYSACCHARIDE / INTRODUCTION --- p.40 / EXPERIMENTAL --- p.43 / RESULTS --- p.45 / DISCUSSION --- p.65 / Chapter 5. --- SIDE EFFECTS DURING IN VIVO PRODUCTION OF TUMOR NECROSIS FACTOR IN EHRLICH ASCITES TUMOR BEARING MICE / INTRODUCTION --- p.70 / EXPERIMENTAL --- p.72 / RESULTS --- p.74 / DISCUSSION --- p.93 / Chapter 6. --- MODIFIED PROCEDURE FOR THE IN VIVO PRODUCTION OF TUMOR NECROSIS FACTOR FOR THE TREATMENT OF EHRLICH ASCITES TUMOR BEARING MICE / INTRODUCTION --- p.98 / EXPERIMENTAL --- p.99 / RESULTS --- p.100 / DISCUSSION --- p.108 / Chapter 7. --- "COMBINED TREATMENTS OF IN VIVO PRODUCTION OF TUMOR NECROSIS FACTOR (TNF) WITH HYPERTHERMIA, METHOTREXATE (MTX), POLYRIBOINOSINIC-POLYRIBOCYTIDYLIC ACID (POLY I.C), N-(PHOSPHONACETYL)-L-ASPARTATE (PALA) ON EAT BEARING MICE" / INTRODUCTION --- p.111 / EXPERIMENTAL --- p.116 / RESULTS --- p.118 / DISCUSSION --- p.133 / Chapter 8. --- EFFECTS OF IN VIVO PRODUCTION OF TUMOR NECROSIS FACTOR ON EHRLICH ASCITES TUMOR CELLS CYTOTOXICITY / INTRODUCTION --- p.138 / EXPERIMENTAL --- p.140 / RESULTS --- p.142 / DISCUSSION --- p.151 / Chapter 9. --- SIDE EFFECTS OF TUMOR NECROSIS FACTOR AND LIPOPOLYSACCHARIDE ON RAT IN VITRO AND IN VIVO / INTRODUCTION --- p.154 / EXPERIMENTAL --- p.157 / RESULTS --- p.159 / DISCUSSION --- p.170 / Chapter 10. --- CONCLUSION AND OUTLOOK --- p.174 / BIBLIOGRAPHY --- p.181